Regeneron and FUJIFILM Diosynth Biotechnologies Enter $3 Billion, 10-Year Manufacturing Supply Agreement

April 22, againRegeneron Announces Collaboration with Leading CDMO CompanyFUJIFILM Diosynth Biotechnologies（FUJIFILMAchieveUnder the new agreement, production and supply will take place at its Holly Springs, North Carolina campus.AgainRegeneron's commercial biologics drug substance will significantly expand its production capacity.AgainRegeneron is already one of the largest biologics manufacturers in the world, and its large-scale manufacturing capacity in the U.S. will nearly double with the use of FUJIFILM Diosynth Biotechnologies' new state-of-the-art biopharmaceutical facility. With technology transfer beginning immediately, the ten-year collaboration is estimated to involve a total investment of over $3 billion.AgainRegeneronContinued and planned investments in infrastructure and manufacturing in New York and North Carolina are expected to exceed $7 billion.$50 Billion! Roche Announces Major Move!）

AgainLeonard Schleifer, MD, PhD, Co-Chairman of the Board, President and Chief Executive Officer of Regeneron, said:“AgainRegeneron is a successful case in the United States. More than 80% of our employees and assets are in the U.S., and all of our drugs approved by the U.S. Food and Drug Administration were invented in our New York labs. Our innovative approach fills our commercial and clinical pipelines with significant new drugs and drives the demand for more manufacturing capacity to fulfill the promise of our science. We are meeting this demand by increasing investments in New York and North Carolina. We are proud to advance biotechnology innovation, which directly improves the health of people around the world, while creating economic growth and high-paying jobs for the United States itself.

This new investment highlightsAgainRegeneron's Commitment to Providing Innovative Medicines for Patients.AgainRegeneron Continues Significant Investment in Its New York Operations, Currently Expanding its Tarrytown Campus with a $3.6 Billion Investment, Creating 1,000 Full-Time High-Skilled Jobs, and Expanding Research, Preclinical Manufacturing, and Support Facilities. Additionally, the company is constructing a brand-new, state-of-the-art fill/finish manufacturing plant in Rensselaer, New York, and has acquired a property exceeding 1 million square feet in Saratoga Springs, New York, for production support activities, with the potential to increase manufacturing capacity.

Fujifilm has 23 subsidiaries in the United States, covering imaging/photography, graphics, life sciences, and semiconductor chemicals businesses, with cumulative revenues of approximately $4.3 billion and more than 7,800 employees. Today, Fujifilm's main growth areas are primarily in life sciences and healthcare, with the company investing over $4 billion in the U.S., as well as in semiconductor materials, where it has invested more than $1 billion for expansion and acquisitions.

AgainDaniel Van Plew, Executive Vice President of Regeneron and General Manager of Industrial Operations and Product Supply, stated:"InAgainRegeneron: "We are fortunate to manufacture some of the best and most innovative therapeutic drugs in the industry, and we are acutely aware of the impact on people's lives as we strive to help treat or even cure devastating diseases. We take our role seriously, and our decision to partner with FUJIFILM reflects our belief that they will meet our high standards and grow alongside us. We are excited about this unique relationship, and we are already working to bring online the capacity of FUJIFILM’s biologics manufacturing facility in Holly Springs, North Carolina."

In the past five years,Regeneron added more than 7,000 jobs, most of which are high-paying R&D and manufacturing positions located in the United States.